Enzalutamide
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Conditions
Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Trial Timeline
Jun 12, 2013 → Jan 10, 2024
NCT ID
NCT01889238About Enzalutamide
Enzalutamide is a phase 2 stage product being developed by Astellas Pharma for Advanced, Androgen Receptor Positive Triple Negative Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01889238. Target conditions include Advanced, Androgen Receptor Positive Triple Negative Breast Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced, Androgen Receptor Positive Triple Negative Breast Cancer were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05404139 | Phase 2 | Recruiting |
| NCT02749903 | Phase 2 | Active |
| NCT02799745 | Phase 2 | Completed |
| NCT02750358 | Phase 2 | Active |
| NCT02605863 | Phase 2 | Terminated |
| NCT02384382 | Phase 2 | Completed |
| NCT02441517 | Approved | Terminated |
| NCT02507570 | Phase 2 | Completed |
| NCT02495974 | Pre-clinical | Completed |
| NCT02203695 | Phase 2 | Completed |
| NCT02288936 | Phase 2 | Completed |
| NCT02669771 | Pre-clinical | Completed |
| NCT02124668 | Phase 2 | Completed |
| NCT03297385 | Phase 2 | Completed |
| NCT02116582 | Approved | Completed |
| NCT02099864 | Phase 2 | Completed |
| NCT01977651 | Approved | Completed |
| NCT02138162 | Phase 1 | Completed |
| NCT01889238 | Phase 2 | Completed |
| NCT01663415 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Advanced, Androgen Receptor Positive Triple Negative Breast Cancer